-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2023-506512-40-00
5
2025-04-16
Acute Kidney Injury
-
2023-506601-19-00
6
2025-04-15
transplantation
-
2024-517582-16-00
5
2025-04-14
rapid sequence induction in the operating room
-
2023-504550-35-00
5
2025-04-03
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2024-511357-22-00
4
2025-03-31
Crohn's disease
-
2022-501489-24-00
5
2025-03-28
First-line treatment of adult subjects with high-risk large B-cell lym
-
2024-516248-24-00
5
2025-03-28
Hereditary Angioedema
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2023-506803-25-01
10
2025-02-26
urgency
-
2024-513533-20-00
5
2025-02-25
Crohn’s Disease or Ulcerative Colitis
-
2024-516049-38-00
4
2025-02-18
CML-CP or CML-AP patients with T315I mutation
-
2023-506656-24-00
5
2025-02-12
Myasthenia gravis
-
2023-506706-40-00
10
2025-02-11
Mantle-Cell Lymphoma
-
2024-513475-41-00
5
2025-02-03
Multiple Sclerosis
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2024-512900-20-00
7
2025-01-30
Non-muscle invasive bladder cancer (NMIBC)
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2023-507544-37-00
5
2025-01-08
patients with end-stage renal disease on chronic peritoneal dialysis a
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi